Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis
AIMS: The objective of this study was to quantify all-cause direct healthcare costs and healthcare resource utilization (HCRU) in the six months before and after COVID-19-associated hospitalization among Medicare fee-for-service (FFS) beneficiaries during the recent Omicron period (March 2023-March 2025). METHODS: This retrospective observational study used 100% Medicare FFS claims data. Beneficiaries aged ≥65 years with a COVID-19 hospitalization between September 2023 and September 2024 and continuous enrollment for six months pre-admission and post-discharge were included. A within-group pre/post design compared mean cumulative per-patient healthcare costs and HCRU during the six-month pre-admission and post-discharge periods, excluding index hospitalization costs. Outcomes were stratified by hospitalization severity and post-discharge care setting. RESULTS: < 0.001). CONCLUSIONS: COVID-19 hospitalization among Medicare FFS beneficiaries is associated with substantial increases in post-discharge healthcare costs and utilization, particularly among patients with greater severity and post-acute care needs. These findings highlight the sustained economic burden of COVID-19 in older adults and underscore the need for targeted post-discharge care strategies.
Authors
- Mohammad A. Chaudhary (ORCID: https://orcid.org/0000-0001-6552-9093)
- Michelle Silver (ORCID: https://orcid.org/0000-0003-1623-7048)
- Santiago M. C. Lopez (ORCID: https://orcid.org/0000-0001-7714-1707)
- Rachel Black
- M. Fernandez (ORCID: https://orcid.org/0000-0002-7361-333X)
- Anan Zhou
- Alon Yehoshua (ORCID: https://orcid.org/0009-0009-2920-916X)
- Tara Ahi
- Rajeev M. Nepal
- Benjamin Yarnoff
- Yu Han (ORCID: https://orcid.org/0009-0008-7876-9596)
Institutions
- Pfizer (United States) (US)
- Thermo Fisher Scientific (United States) (US)
- Genesis Research Institute (JP)
- Renesas Electronics (Japan) (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-09-01
- DOI
- https://doi.org/10.1080/13696998.2026.2722823
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer